Considering the critical functional roles and putative prognostic value of specific HOX genes in cancer, including in malignant glioma, and their complex molecular interactions with upstream regulators and downstream targets, it becomes clear that additional studies are necessary to better understand how HOX genes operate in glioma but also possibly in WDSTS, and whether they may be therapeutically explored in the clinics. This evidence concerns the gene KMT2A and glioma.